Yoshiyuki Shibasaki

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Yuichiro Yamada, Hideki Katagiri, Yoshiyuki Hamamoto et al. · The Lancet Diabetes & Endocrinology · 2020 · 223 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study

Akihiko Asahina, Takafumi Etoh, Atsuyuki Igarashi et al. · The Journal of Dermatology · 2016 · 84 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan

Fumihiko Sakai, Koichi Hirata, Hisaka Igarashi et al. · The Journal of Headache and Pain · 2022 · 52 citations · Full text

Business, Insurance, Health Assessment +13

Impact of changes in social anxiety on social functioning and quality of life in outpatients with schizophrenia: A naturalistic longitudinal study

Takahiro Nemoto, Takashi Uchino, Sayaka Aikawa et al. · Journal of Psychiatric Research · 2020 · 35 citations · Full text

Medicine, Psychiatry, Psychology +15

Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan

Isao Sakaida, Koji Nakajima, Kiwamu Okita et al. · Journal of Gastroenterology · 2015 · 33 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13